Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil 23 mg vs 10 mg in Severe Alzheimer's Disease
NCT01539031Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of donepezil in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Mar 2012; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01539031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01539031.